STOCK TITAN

Acer Therapeutics Inc - ACER STOCK NEWS

Welcome to our dedicated news page for Acer Therapeutics (Ticker: ACER), a resource for investors and traders seeking the latest updates and insights on Acer Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acer Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acer Therapeutics's position in the market.

Rhea-AI Summary
Acer Therapeutics reacquires worldwide rights to OLPRUVA from Relief Therapeutics, excluding Geographical Europe. Relief receives upfront payment of $10 million and potential total payments of up to $56.5 million. Acer regains economic rights without profit sharing and plans to reinvest in potential expansion opportunities. Relief retains development and commercialization rights in Geographical Europe. OLPRUVA now available in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
109.84%
Tags
-
Rhea-AI Summary
Acer Therapeutics Inc. (Nasdaq: ACER) has made OLPRUVA™ (sodium phenylbutyrate) kits available in all dosage strengths and ready to ship to patients. The company reported financial results for the second quarter ended June 30, 2023, with a cash position of $1.6 million. Acer anticipates attaining OLPRUVA™ commercial insurance coverage and Medicaid patient insurance coverage in Q3 2023. They also expect to complete enrollment in their pivotal Phase 3 DiSCOVER trial of EDSIVO™ in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
-
Rhea-AI Summary
Acer Therapeutics provides an update on the commercial launch of OLPRUVA™, a treatment for certain UCD patients. The drug availability is now expected in mid-June 2023, ahead of schedule. Acer has also made progress in discussions with payers for reimbursement and has seen increased physician interest in using OLPRUVA™. The company expects to begin accepting prescriptions in mid-June 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-56.77%
Tags
Acer Therapeutics Inc

Nasdaq:ACER

ACER Rankings

ACER Stock Data

16.15M
18.37M
13.78%
29.91%
2.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newton

About ACER

acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica